Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621305 | 1.00 | SIGMAR1 (0.52) | SIGMAR1CCR5TRPM8ALDH1A1CYP3A4 | |
| SCHEMBL2621307 | 1.00 | SIGMAR1 (0.52) | SIGMAR1CCR5TRPM8ALDH1A1CYP3A4 | |
| SCHEMBL19139368 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CCR5ALDH1A1CYP3A4TSHR | |
| SCHEMBL129763 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CCR5ALDH1A1CYP3A4TSHR | |
| SCHEMBL2621386 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CCR5ALDH1A1CYP3A4TSHR | |
| SCHEMBL2621297 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CCR5ALDH1A1CYP3A4TSHR | |
| SCHEMBL1058888 | 0.87 | SIGMAR1 (0.60) | SIGMAR1CCR5ALDH1A1TSHRENPP2 | |
| SCHEMBL4803972 | 0.85 | SIGMAR1 (0.55) | SIGMAR1CCR5ALDH1A1ENPP2ABCB1 | |
| SCHEMBL4803965 | 0.85 | SIGMAR1 (0.55) | SIGMAR1CCR5ALDH1A1ENPP2ABCB1 | |
| SCHEMBL4805754 | 0.85 | SIGMAR1 (0.55) | SIGMAR1CCR5ALDH1A1ENPP2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-8722082-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-13 | — | — | US | disclosed |
| US-8722082-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-13 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054384-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SIGMAR1 2646/4885CCR5 414/4885TRPM8 4521/4885 |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SIGMAR1 2646/4885CCR5 414/4885TRPM8 4521/4885 |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ABCB4, CETP, SGMS1 | SIGMAR1 2178/4885CCR5 406/4885TRPM8 4678/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SIGMAR1 2708/4885CCR5 457/4885TRPM8 4560/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SIGMAR1 2708/4885CCR5 457/4885TRPM8 4560/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | SIGMAR1 2216/4885CCR5 798/4885TRPM8 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.